Medtronic (NYSE: MDT) has had its share of setbacks this year. But the medtech giant has also made moves that could set it up to significantly change how chronic health conditions such as atrial fibrillation are treated.
CEO Geoff Martha has insisted that the world’s largest medical device company can make good on its goals.
Here are the top Medtronic stories on MassDevice that got us to this point.
10. Reduced guidance amid slower procedures and supply recovery
Despite the challenges during the company’s most recent quarter, Martha said the company has businesses where strategy and execution are yielding results.
9. GE Healthcare, Medtronic collaborate in outpatient care space
The partnership centers around the needs and demand for care at ambulatory surgery centers (ASCs) and office-based labs (OBLs).
8. Medtronic Neurovascular goes remote with Avail Medsystems deal
The three-year agreement is worth tens of millions of dollars.
7. Spinoff planned for patient monitoring, respiratory intervention businesses
“We are executing on our portfolio management strategy.”
6. RDN trial fails to beat hypertension drugs
The company said it submitted the final module of the Symplicity Spyral Premarket Approval package to the FDA for review and approval.
5. The road to a robot: Medtronic’s development process for its Hugo RAS system
“We looked at the current state of robotics going back 10-plus years, and we realized there was an opportunity for us to come in.”
4. Medtronic begins distributing Acutus AcQCross sheath-compatible septal crossing devices
In April, Acutus agreed to sell its left-heart access portfolio to Medtronic for $50 million.
3. Medtronic, DaVita to form a new kidney care company
Medtronic’s renal care solutions business — which includes renal access, acute therapies and chronic therapies — will get rolled into the new company.
2. Why Affera’s cardiac ablation technology is worth $1B to Medtronic
Affera started in 2014 with a simple goal that paid off when Medtronic bought the company this year. Achieving that goal, however, took some unconventional and sometimes difficult design choices.
1. Medtronic completes Affera acquisition
The acquisition expanded the company’s cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform that encompasses a differentiated, fully integrated diagnostic, focal pulsed-field and radiofrequency ablation system.